First-in-man combination phase I study of TAS-114 and S-1 in patients (pts) with advanced solid tumors.

2544 Background: TAS-114 is a first-in-class oral deoxyuridine triphosphatase inhibitor, which acts as a modulator of the pyrimidine nucleotide metabolic pathway. We are conducting a first combinat...